Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price Target
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsReiterationPrice Target
Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $5 price target.
Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $5 price target.